From Waiting Rooms to Boardrooms: How Patient Advocacy Groups Are Reshaping Drug Development
Organized patient communities are no longer content to wait for pharmaceutical companies to determine which diseases deserve attention. Across the United States, advocacy-driven coalitions are securing seats at research tables once reserved exclusively for industry scientists and regulators, fundamentally altering how drugs are conceived, tested, and approved.